![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
CPCA - a new approach to define Nitrosamine AI limit (Pharma Growth Hub) View |
![]() |
Is the Less Than Lifetime (LTL) Limit applies to NITROSAMINES (Pharma Growth Hub) View |
![]() |
Which limits apply for Nitrosamines in medicinal products (Pharma Growth Hub) View |
![]() |
Nitrosamine Impurities, NDSRIs and Setting Acceptable Intake (AI) Limits @ToxGyan (ToxGyan) View |
![]() |
How to derive an AI for new N-Nitrosamine (Pharma Growth Hub) View |
![]() |
How to Define Limit For Newly Identified Nitrosamine Impurity (Pharma Growth Hub) View |
![]() |
How to predict the potency category of Nitrosamine as per new EMA updates (Pharma Growth Hub) View |
![]() |
What defines the Carcinogenic Potency of Nitrosamine (Pharma Growth Hub) View |
![]() |
Calculating limits for carcinogens: AI, PDE, and less than lifetime as per ICH M7 (Fernanda Waechter) View |
![]() |
How to Decide the Need of Testing Nitrosamine Impurities into Pharmaceuticals (Pharma Growth Hub) View |